Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endogenous thrombin potential

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Endogenous thrombin potential. Displaying page 1 of 1.
    EudraCT Number: 2011-002084-20 Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants Start Date*: 2011-07-28
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex...
    Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002345-38 Sponsor Protocol Number: 12/0033/CTU/IMM/001 Start Date*: 2012-10-30
    Sponsor Name:University College London
    Full Title: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Medical condition: Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002645-38 Sponsor Protocol Number: BIOMARCHA Start Date*: 2012-09-04
    Sponsor Name:CRESIB-Barcelona Centre for International Health Research
    Full Title: Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases
    Medical condition: The study will be held in 63 patients with chronic Chagas Disease and 63 healthy people
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017288-40 Sponsor Protocol Number: P06447 Start Date*: 2010-02-03
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A Randomized, Open-Label, Comparative, Multicenter Trial to Compare the Effects on Metabolic Parameters of Two NOMAC-E2 Batches (Pivotal Phase III and Commercial Batch) and a Monophasic COC Contain...
    Medical condition: Hormonal oral contraception in healthy women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003807-32 Sponsor Protocol Number: BT200-02 Start Date*: 2020-12-16
    Sponsor Name:Medical University of Vienna
    Full Title: A Phase 2a Multiple Dose “Basket Design” Study Of The Safety, Tolerability, And Pharmacologic Activity Of BT200 In Patients With Hereditary Bleeding Disorders
    Medical condition: - Patients with severe congenital hemophilia A - Patients with mild-moderate hemophilia A - Heterozygous carriers of hemophilia A - Patients with VWD Type 1, e.g. “Vicenza” type - Acquired Von Will...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001674-80 Sponsor Protocol Number: ARG-E04 Start Date*: 2005-06-13
    Sponsor Name:Mitsubishi Pharma Corporation
    Full Title: A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients u...
    Medical condition: Stable coronary artery disease (CAD) or unstable angina (troponin negative, i.e. within the normal range for the study site) with low to moderate anatomic risk and a requirement for elective percut...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10011078 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000740-21 Sponsor Protocol Number: LEX-210 Start Date*: 2022-04-08
    Sponsor Name:Octapharma AG
    Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.
    Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10009731 Coagulation disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003002-27 Sponsor Protocol Number: MIT-Es001-C303 Start Date*: 2020-10-14
    Sponsor Name:Estetra SRL
    Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10030971 Oral contraceptive LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001885-27 Sponsor Protocol Number: B7841002 Start Date*: 2017-05-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECT...
    Medical condition: Severe hemophilia A or B, with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    20.0 100000004850 10053753 Hemophilia A without inhibitors LLT
    20.0 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adults Gender: Male
    Trial protocol: PL (Completed) ES (Completed) FR (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-006026-28 Sponsor Protocol Number: A3481066 Start Date*: 2006-09-25
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy
    Medical condition: Patients who are scheduled to undergo routine radical prostatectomy performed under a standardized regimen of general anesthesia, and who are expected to experience moderate to severe postsurgical ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001785-26 Sponsor Protocol Number: 14-505 Start Date*: 2016-02-15
    Sponsor Name:Portola Pharmaceuticals, Inc.
    Full Title: Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Have Acute Major Bleeding (ANNEXA-4).
    Medical condition: Uncontrolled bleeding in patients who have taken either a direct factor Xa inhibitor (novel oral anticoagulants) or an indirect factor Xa inhibitor (low molecular weight heparins).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022097 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004039-10 Sponsor Protocol Number: NL81112.041.22 Start Date*: 2022-06-24
    Sponsor Name:UMC Utrecht - Van Creveldkliniek
    Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study
    Medical condition: Congenital hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022726-33 Sponsor Protocol Number: 251001 Start Date*: 2011-03-24
    Sponsor Name:Baxter Innovations GmbH
    Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo...
    Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:57:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA